Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA5A | P35218 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27718168 | 0.98 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL617121 | 0.87 | RIPK1 (0.52) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL3196637 | 0.82 | APP (0.62) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL15794568 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL1636840 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL1247145 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL3932455 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL3244369 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL334808 | 0.80 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL10336504 | 0.80 | ALDH1A1 (0.66) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| CN-119241559-A | Quinazoline macrocyclic compound serving as HPK1 kinase inhibitor and preparation method and application thereof | 深圳市新樾生物科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024238406-A1 | FUROPYRIDINE COMPOUNDS AS P53 MUTANT STABILIZER AND USES THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024150815-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | 田辺三菱製薬株式会社 | 2024-07-18 | — | — | WO | disclosed |
| CN-117843579-A | Benzo heterocycle coupled catechol derivative and preparation method and application thereof | 暨南大学 | 2024-04-09 | — | — | CN | disclosed |
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-0060426-B1 | N-(2,2,2-TRIFLUOROETHYL)-N-ALKYL-AZOLYLOXYACETIC-ACID AMIDES, THEIR PREPARATION AND USE AS HERBICIDES AND INTERMEDIATES FOR THEIR PREPARATION | BAYER AG (DE) | 1986-04-23 | — | — | EP | disclosed |
| EP-0129506-A2 | Heterocyclically substituted thio(cyclo)alkane polycarboxylic acids | CIBA-GEIGY AG (CH) | 1984-12-27 | — | — | EP | disclosed |
| US-4465504-A | Herbicidally active novel N-(2,2,2-trifluoroethyl)-N-alkyl-azolyloxyacetic acid amides and intermediates therefor | BAYER AKTIENGESELLSCHAFT (DE) | 1984-08-14 | — | — | US | disclosed |
| US-4455428-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-06-19 | — | — | US | disclosed |
| US-4447617-A | Process for the preparation of 2-amino-6-nitrobenzothiazole | EASTMAN KODAK COMPANY (US) | 1984-05-08 | — | — | US | disclosed |
| US-4408055-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-10-04 | — | — | US | disclosed |
| EP-0060426-A2 | N-(2,2,2-trifluoroethyl)-N-alkyl-azolyloxyacetic-acid amides, their preparation and use as herbicides and intermediates for their preparation | BAYER AG (DE) | 1982-09-22 | — | — | EP | disclosed |
| EP-0004623-B1 | PROCESS FOR THE PREPARATION OF AROMATIC AMINES | BAYER AG (DE) | 1981-07-01 | — | — | EP | disclosed |
| US-4247629-A | FOR DIFFUSION TRANSFER | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1981-01-27 | — | — | US | disclosed |
| EP-0004623-A1 | Process for the preparation of aromatic amines | BAYER AG (DE) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | SMN1; SMN2 2951/4885ALDH1A1 4330/4885HTT 4372/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | SMN1; SMN2 4531/4885ALDH1A1 1008/4885HTT 531/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | SMN1; SMN2 566/4885ALDH1A1 579/4885HTT 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.